Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus
Tirzepatide treatment for T2DM in patients with MASLD significantly improved liver steatosis and injury, surrogate markers of liver fibrosis, and diabetes status, and reduced body weight.
Authors
- Chisa Kondo
- Ai Nakagawa‐Iwashita
- Norio Itokawa (ORCID: https://orcid.org/0009-0002-2390-6692)
- Kaori Koyano (ORCID: https://orcid.org/0000-0001-6764-5485)
- Masato Iwabu (ORCID: https://orcid.org/0000-0002-1930-9046)
- Yuta Hasegawa (ORCID: https://orcid.org/0000-0002-7647-9623)
- Tomomi Okubo (ORCID: https://orcid.org/0000-0003-1244-4736)
- Korenobu Hayama
- Kenta Suzuki (ORCID: https://orcid.org/0000-0003-2309-6028)
- Yūji Yoshida (ORCID: https://orcid.org/0000-0002-3302-3140)
- Hiroki Ono (ORCID: https://orcid.org/0000-0003-3723-2967)
- Katsuhiko Iwakiri (ORCID: https://orcid.org/0000-0002-5558-6104)
- Zento Yamada (ORCID: https://orcid.org/0000-0001-6958-6706)
- Michika Kitamura
- Masanori Atsukawa (ORCID: https://orcid.org/0000-0003-3374-7111)
- Mototsugu Nagao (ORCID: https://orcid.org/0000-0001-6880-5161)
- Tadamichi Kawano
- Takahiro Rokugo
- Chikako Nagao
- Taeang Arai
- Tetsuyuki Higashi
Institutions
- Nippon Medical School (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1111/hepr.14241
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35